Does the media refer more to MNKD or CLDX?

In the previous week, MannKind had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for MannKind and 17 mentions for Celldex Therapeutics. MannKind's average media sentiment score of 0.89 beat Celldex Therapeutics' score of 0.74 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or MNKD?

In the previous week, MannKind had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 19 mentions for MannKind and 10 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.13 beat MannKind's score of 0.89 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MNKD or ZBIO?

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.46 $5.86M -$0.07 N/A Zenas BioPharma $10M 199.10 -$377.74M -$8.47 N/A

Does the media refer more to MNKD or ZBIO?

In the previous week, MannKind had 14 more articles in the media than Zenas BioPharma. MarketBeat recorded 19 mentions for MannKind and 5 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.24 beat MannKind's score of 0.89 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, INVA or MNKD?

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $420.69M 3.69 $271.17M $6.01 3.50 MannKind $348.97M 3.46 $5.86M -$0.07 N/A

Is INVA or MNKD more profitable?

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% MannKind -6.63% -11.21% -3.92%

Does the media refer more to INVA or MNKD?

In the previous week, MannKind had 11 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for MannKind and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat MannKind's score of 0.89 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MNKD or NVAX?

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.46 $5.86M -$0.07 N/A Novavax $1.12B 1.07 $440.30M -$0.58 N/A

Is MNKD or NVAX more profitable?

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% Novavax -14.73% -14.82% 1.23%

Does the media favor MNKD or NVAX?

In the previous week, MannKind had 13 more articles in the media than Novavax. MarketBeat recorded 19 mentions for MannKind and 6 mentions for Novavax. MannKind's average media sentiment score of 0.89 beat Novavax's score of 0.15 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MannKind (MNKD) Competitors

$3.90 -0.21 (-4.99%)

As of 11:45 AM Eastern

Compare

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

Should you buy MannKind stock or one of its competitors? MarketBeat compares MannKind with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MannKind include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does MannKind compare to Celldex Therapeutics?

MannKind (NASDAQ:MNKD) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

MannKind currently has a consensus price target of $9.34, indicating a potential upside of 139.28%. Celldex Therapeutics has a consensus price target of $54.62, indicating a potential upside of 45.95%. Given MannKind's higher possible upside, equities analysts plainly believe MannKind is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

MannKind has higher revenue and earnings than Celldex Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A

In the previous week, MannKind had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for MannKind and 17 mentions for Celldex Therapeutics. MannKind's average media sentiment score of 0.89 beat Celldex Therapeutics' score of 0.74 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

MannKind beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does MannKind compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, MannKind had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 19 mentions for MannKind and 10 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.13 beat MannKind's score of 0.89 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.60	$263.86M	-$1.78	N/A
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A

MannKind has a net margin of -6.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. MannKind's return on equity of -11.21% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
MannKind	-6.63%	-11.21%	-3.92%

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals presently has a consensus price target of $20.80, indicating a potential upside of 132.01%. MannKind has a consensus price target of $9.34, indicating a potential upside of 139.28%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

BioCryst Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Zenas BioPharma?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, indicating that its share price is 196% less volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	199.10	-$377.74M	-$8.47	N/A

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-99.99%	-58.06%

MannKind presently has a consensus price target of $9.34, indicating a potential upside of 139.28%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 40.42%. Given MannKind's higher probable upside, research analysts plainly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, MannKind had 14 more articles in the media than Zenas BioPharma. MarketBeat recorded 19 mentions for MannKind and 5 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.24 beat MannKind's score of 0.89 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does MannKind compare to Innoviva?

Innoviva (NASDAQ:INVA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A

In the previous week, MannKind had 11 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for MannKind and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat MannKind's score of 0.89 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Innoviva presently has a consensus price target of $36.20, indicating a potential upside of 72.24%. MannKind has a consensus price target of $9.34, indicating a potential upside of 139.28%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
MannKind	-6.63%	-11.21%	-3.92%

Summary

Innoviva beats MannKind on 11 of the 16 factors compared between the two stocks.

How does MannKind compare to Novavax?

MannKind (NASDAQ:MNKD) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.07	N/A
Novavax	$1.12B	1.07	$440.30M	-$0.58	N/A

49.6% of MannKind shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MannKind currently has a consensus price target of $9.34, indicating a potential upside of 139.28%. Novavax has a consensus price target of $13.00, indicating a potential upside of 78.45%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, MannKind had 13 more articles in the media than Novavax. MarketBeat recorded 19 mentions for MannKind and 6 mentions for Novavax. MannKind's average media sentiment score of 0.89 beat Novavax's score of 0.15 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Summary

MannKind beats Novavax on 10 of the 17 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.21B	$3.65B	$6.86B	$12.37B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-55.78	23.06	27.45	23.66
Price / Sales	3.46	212.49	495.52	78.38
Price / Cash	62.22	165.25	51.74	58.30
Price / Book	-22.97	7.92	9.91	5.85
Net Income	$5.86M	$23.81M	$3.61B	$336.64M
7 Day Performance	-5.45%	-1.14%	-0.29%	0.02%
1 Month Performance	-8.33%	-7.49%	-3.96%	-5.24%
1 Year Performance	3.31%	39.62%	22.83%	17.56%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	2.799 of 5 stars	$3.91 -5.0%	$9.34 +139.3%	+6.2%	$1.21B	$348.97M	N/A	400	Upcoming Earnings Analyst Forecast
CLDX Celldex Therapeutics	2.8668 of 5 stars	$35.65 +1.0%	$52.77 +48.0%	+68.7%	$2.77B	$1.54M	N/A	150	Upcoming Earnings Analyst Forecast
BCRX BioCryst Pharmaceuticals	3.5837 of 5 stars	$9.58 +2.6%	$20.80 +117.1%	+12.4%	$2.37B	$874.84M	N/A	530	Positive News Upcoming Earnings Short Interest Decrease
ZBIO Zenas BioPharma	3.9237 of 5 stars	$32.82 +8.0%	$44.29 +34.9%	+104.9%	$1.92B	$10M	N/A	N/A	Positive News
INVA Innoviva	3.1718 of 5 stars	$21.30 -0.7%	$36.20 +70.0%	+15.1%	$1.58B	$411.33M	3.54	100	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does MannKind compare to Celldex Therapeutics?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Summary

How does MannKind compare to Zenas BioPharma?

Summary

How does MannKind compare to Innoviva?

Summary

How does MannKind compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does MannKind compare to Celldex Therapeutics?

Do analysts recommend MNKD or CLDX?

Which has better earnings & valuation, MNKD or CLDX?

Does the media refer more to MNKD or CLDX?

Which has more volatility and risk, MNKD or CLDX?

Do institutionals and insiders have more ownership in MNKD or CLDX?

Is MNKD or CLDX more profitable?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Does the media prefer BCRX or MNKD?

Which has stronger valuation and earnings, BCRX or MNKD?

Is BCRX or MNKD more profitable?

Which has more volatility and risk, BCRX or MNKD?

Do insiders and institutionals have more ownership in BCRX or MNKD?

Do analysts prefer BCRX or MNKD?

Summary

How does MannKind compare to Zenas BioPharma?

Which has more volatility & risk, MNKD or ZBIO?

Do institutionals & insiders believe in MNKD or ZBIO?

Which has preferable valuation & earnings, MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Do analysts recommend MNKD or ZBIO?

Does the media refer more to MNKD or ZBIO?

Summary

How does MannKind compare to Innoviva?

Do insiders and institutionals believe in INVA or MNKD?

Which has better earnings & valuation, INVA or MNKD?

Does the media refer more to INVA or MNKD?

Which has more volatility and risk, INVA or MNKD?

Do analysts prefer INVA or MNKD?

Is INVA or MNKD more profitable?

Summary

How does MannKind compare to Novavax?

Which has better valuation and earnings, MNKD or NVAX?

Do insiders & institutionals have more ownership in MNKD or NVAX?

Do analysts prefer MNKD or NVAX?

Is MNKD or NVAX more profitable?

Does the media favor MNKD or NVAX?

Which has more risk and volatility, MNKD or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools